The lesson that entrepreneurs and VCs seem to be taking from the fast-paced ophthalmology sector is the need for shorter development time frames and clinical candidates with reduced risk. Among others, MacuSight, Danube, and Lux, profiled here, are to one extent or another revisiting the existing pharmacopeia to test ophthalmic indications for existing compounds.
Blink, and you may miss it.
The ophthalmology field is moving fast. For evidence, look no further than Genentech Inc. 's recently approved ranibizumab (Lucentis)...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.
Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
Multi-blockbuster falls short in a giant cell arteritis study.
Multi-blockbuster falls short in a giant cell arteritis study.
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
